messag gilead report top bottom line miss hiv/hbv
franchis increas yoy decreas qoq hcv franchis
yoy qoq total product sale yoy qoq respect
yescarta sale increas oper margin
decreas see sever late stage
drug nash immunolog well yescarta potenti revenu driver
futur hcv declin remain effect thu reiter neutral rate
complet author cancer center track certifi enough
center reach yescarta-elig patient approxim two-third
yescarta patient cover commerci fee-for-servic plan roughli one-third
cover medicar manag expect eu approv aggress
nhl line studi continu enrol patient
hiv franchis crucial off-set eros hcv eros opinion
launch biktarvi compar genvoya manag expect biktarvi
even overtak genvoya gener expect biktarvi launch explain
qoq decreas dynam accord manag biktarvi recommend hh
one initi regimen adult adolesc hiv howev launch
may come cost eros genvoya demand due switch
one-third switch genvoya regardless manag believ biktavi
becom largest hiv product
manag continu see hcv eros bottom chang
nash program enrol two phase program readout may occur
final late stage program ra inhibitor filgotinib underway
made adjust model base perform guidanc
manag commentari earn call afternoon modestli
decreas hiv/hbv franchis estim beyond due lower
expect revenu growth first quarter addit slightli lower hcv
estim reflect continu rapid decreas sale
estim hcv revenu due increas competit price pressur
increment decreas futur year manag believ hcv revenu
like flatten beyond tax rate remain subsequ year
result recent tax reform legisl adjust ep
declin total oper revenu total product revenu
valuat risk
valuat valuat base gild grow hiv/hbv franchis driven larg
estim taf-bas product includ genvoya odefsey descovi
bictegravir idelalisib zydelig cll/inhl kite axi-cel eu note
includ risk-adjust estim gild nash pipelin neutral
rate base sum discount cash flow use unchang
discount rate termin growth rate plu current net cash
page analyst certif import disclosur
upsid risk upsid risk valuat invest thesi includ
favor clinic outcom oncolog cardiolog program well setback
competitor hiv stronger-than-expect intern uptak antivir could
spur growth new invest ex-u posit clinic readout gild mid
downsid risk downsid risk valuat invest thesi includ
addit safeti issu gild drug faster-than-expect declin hcv
franchis due price competit pressur declin address popul
page analyst certif import disclosur
million except per-shar figur
royalti collab contract revenu
good
research develop
sell gener administr
earn loss incom tax
provis incom tax
revenu gener sustiva compon atripla book revenu atripla sale line expens cog line
leitari sale includ product sale includ report anti-vir gener product revenu categori primarili cayston lexiscan
includ flolan transfer payment gsk
includ royalti us ambisom sale astella tamiflu roch macugen eyetech vistid potenti mileston ambrisentan macugen medarex royalti buy-out
interest expens includ restat incorpor fasb apb fasb apb account appli estim beyond
includ vemlidi revenu prior
includ yescarta revenu
compani data guggenheim secur llc
page analyst certif import disclosur
